By Candice Choi

Don’t even think of putting the mask away anytime soon.

Despite the expected arrival of COVID-19 vaccines in just a few weeks, it could take several months — probably well into 2021 — before things get back to something close to normal in the U.S. and Americans can once again go to the movies, cheer at an NBA game or give Grandma a hug.

The first, limited shipments of the vaccine would mark just the beginning of what could be a long and messy road toward the end of the pandemic that has upended life and killed more than a quarter-million people in the U.S. In the meantime, Americans are being warned not to let their guard down.

“If you’re fighting a battle and the cavalry is on the way, you don’t stop shooting; you keep going until the cavalry gets here, and then you might even want to continue fighting,” Dr. Anthony Fauci, the nation's top infectious-disease expert, said last week.

This week, AstraZeneca became the third vaccine maker to say early data indicates its shots are highly effective. Pfizer last week asked the U.S. Food and Drug Administration for emergency authorization to begin distributing its vaccine, and Moderna is expected to do the same any day. Federal officials say the first doses will ship within a day of authorization.

But most people will probably have to wait months for shots to become widely available. The Pfizer and Moderna vaccines also each require two doses, meaning people will have to go back for a second shot after three and four weeks, respectively, to get the full protection.

Moncef Slaoui, head of the U.S. vaccine development effort, said on CNN on Sunday that early data on the Pfizer and Moderna shots suggest about 70% of the population would need to be vaccinated to achieve herd immunity — a milestone he said is likely to happen in May.

But along the way, experts say the logistical challenges of the biggest vaccination campaign in U.S. history and public fear and misinformation could hinder the effort and kick the end of the pandemic further down the road.

“It’s going to be a slow process and it’s going to be a process with ups and downs, like we’ve seen already,” said Dr. Bill Moss, an infectious-disease expert at Johns Hopkins University.

SHOTS IN ARMS

Once federal officials give a vaccine the go-ahead, doses that are already being stockpiled will be deployed with the goal of “putting needles in people’s arms” within 24 to 48 hours, said Paul Mango, a U.S. Department of Health and Human Services official involved in the Operation Warp Speed effort to develop COVID-19 vaccines.

Those first shipments are expected to be limited and will be directed to high-risk groups at designated locations, such as front-line health care workers at hospitals.

Federal and state officials are still figuring out exactly how to prioritize those most at risk, including the elderly, prison inmates and homeless people. By the end of January, HHS officials say, all senior citizens should be able to get shots, assuming a vaccine becomes available by the end of 2020.

For everyone else, they expect widespread availability of vaccines would start a couple of months later.

To make shots easily accessible, state and federal officials are enlisting a vast network of providers, such as pharmacies and doctor’s offices.

But some worry long lines won’t be the problem.

“One of the things that may be a factor that hasn’t been discussed that much is: ‘How many will be willing to be vaccinated?’” said Christine Finley, director of Vermont's immunization program. She noted the accelerated development of the vaccine and the politics around it have fueled worries about safety.

Even if the first vaccines prove as effective as suggested by early data, they won’t have much impact if enough people don’t take them.

NO MAGIC BULLET

Vaccines aren’t always effective in everyone: Over the past decade, for example, seasonal flu vaccines have been effective in about 20% to 60% of people who get them.

AstraZeneca, Pfizer, and Moderna say early trial data suggests their vaccine candidates are about 90% or more effective. But those rates could change by the time the studies end.

Also, the definition of “effective” can vary.

Rather than prevent infection entirely, the first COVID-19 vaccines might only prevent illness. Vaccinated people might still be able to transmit the virus, another reason experts say masks will remain crucial for some time.

Another important aspect of vaccines: They can take a while to work.

The first shot of a COVID-19 vaccine might bring about a degree of protection within a couple of weeks, meaning people who get infected might not get as sick as they otherwise would. But full protection could take up to two weeks after the second shot -- or about six weeks after the first shot, said Deborah Fuller, a vaccine expert at the University of Washington.

People who don’t understand that lag could mistakenly think the vaccine made them sick if they happen to come down with COVID-19 soon after a shot. People might also blame the vaccine for unrelated health problems and amplify those fears online.

“All you need is a few people getting on social media,” said Moss of Johns Hopkins University.

There's also the possibility of real side effects. COVID-19 vaccine trials have to include at least 30,000 people, but the chances of a rare side effect turning up are more likely as growing numbers of people are vaccinated.

Even if a link between the vaccine and a possible side effect seems likely, the distribution of shots might not be halted if the risk is deemed small and is outweighed by the benefits, said Dr. Wilbur Chen, a vaccine expert at the University of Maryland.

But Chen said public health officials will need to clearly explain the relative risks to avoid public panic.

Depending on whether the virus mutates in coming years and how long the vaccine’s protection lasts, booster shots, later on, may also be necessary, said Dr. Edward Belongia, a vaccine researcher with the Marshfield Clinic Research Institute in Wisconsin.

Belongia and many others say the coronavirus won’t ever be stamped out and will become one of the many seasonal viruses that sicken people. How quickly will vaccines help reduce the threat of the virus to that level?

“At this point, we just need to wait and see,” Belongia said.

——

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Share:
More In Science
Amazon Funds Amogy to Commercialize Ammonia-Powered Cargo-Shipping Vessels, Decarbonize Transportation
Amazon is betting that ammonia could be the fuel of the future, participating in a Series A round for the Brooklyn-based company Amogy in December. Amogy aims to de-carbonize transportation with a clean energy system that uses ammonia as a renewable fuel. Amogy is partnering with Amazon on its first commercial product - an ammonia-powered cargo-shipping vessel. Amogy CEO Seonghoon Woo joins Cheddar Climate to discuss.
Congressional Democrats Demand Answers From Crypto Miners Over Environmental Impact
Cryptocurrency is expected to become a part of our daily lives — but what sort of environmental impact does it have? As the U.S. becomes the crypto mining capital of the world, climate advocates are worried about mining companies reopening old coal plants, using massive amounts of energy, wasteful hardware, and more. Congressional Democrats led by Senator Elizabeth Warren are demanding answers from mining firms about their electricity use and waste levels. John Belizaire, CEO of Soluna Computing, joins Cheddar Climate to discuss the congressional letters, how crypto mining can become a green industry, and more.
Indirect Driver Assistance Monitoring Significantly Worse Than Camera-Based Systems: Report
Driver assistance monitoring systems are meant to keep the driver's eyes on the road, but according to a report from AAA, different ways of monitoring provide significantly different results. The study found that direct camera-based systems that scanned the driver's eye movements were faster and more reliable than those indirect systems that looked at steering-wheel input. Megan McKernan, the manager of automotive services for the Automobile Club of Southern California, joined Cheddar to discuss the findings. "Triple-A is recommending that automakers include both direct and indirect systems just to really prevent consumers from trying to misuse these systems," she said, noting that neither system on its own is not foolproof.
Wave Neuroscience Tech Looks to Improve Brain Care for Pro Athletes
Wave Neuroscience is a neurological health tech company that specializes in clinical and at-home personalized brain stimulation technology. Erik Won, president and chief medical officer and Fred Walke, CEO, joined Cheddar's Opening Bell to discuss their company's hopes for allowing patients to identify and treat unique brain disorders while empowering them to understand their unique neurological makeups — including for the high-stress positions of professional athletes. "We have a mobile device that provides a very light stimulation that gives them a therapy that gives them confidence so there's a just knowing that they're doing something for it," said Walke. "But it also helps them get back into a rhythm. It helps their brain synchronize around certain frequencies that that we target, and it helps them really understand that they've done everything they can to get to their highest level of success."
Lawmakers Look Into Bitcoin Mining Companies' Energy Use
Democratic lawmakers are now calling on Bitcoin mining companies in the U.S. to assess how much electricity they use and how it could all potentially impact residents and the environment in the near future. Since its conception, crypto mining has been at the center of a debate. The question is: Is crypto mining playing a key role in renewable energy or could it totally derail U.S. climate goals? Host of The Wendy O show Wendy O, joined Cheddar to discuss more.
Athletic Greens Raises $115 Million to Expand Footprint of Nutritional Drink
Nutritional supplement beverage company Athletic Greens has achieved unicorn status. The company announced a new $115 million funding round, bringing its valuation to $1.2 billion. The company's flagship product AG1 combines 75 different vitamins, minerals, and other nutrients into one daily serving. Athletic Greens says it is poised to reach the millions of consumers who are currently driving the health and wellness market's exponential growth. Athletic Greens founder and CEO Chris Ashenden joins Cheddar News' Closing Bell to discuss.
Northeast Recovering From Weekend Snow Storm
A powerful winter storm hit the Northeast over the weekend leaving 100,000 New Yorkers in the dark as well as snowfall up to 30.9 inches in parts of Massachusetts. The nor'easter hit with blizzard conditions of wind speed and poor visibility.
Load More